Skip to main content
. Author manuscript; available in PMC: 2016 Feb 5.
Published in final edited form as: Expert Opin Pharmacother. 2015 Apr 7;16(7):955–960. doi: 10.1517/14656566.2015.1025750

Table 2.

Major phase 3 trials involving biologics in combination with chemotherapy in the localized gastric cancer setting

Trial No. of patients Treatment
arms		 HR for
OS/Death

(P-value)		 Survival
comparison
Suntharalingam et al 26 (RTOG 0436 trial) 344 Cisplatin, paclitaxel and cetuximab plus radiation vs cisplatin and paclitaxel plus radiation 0.92 (0.70) 2-year OS rate: 44% vs 41.7%
Crosby et al 27 (SCOPE-1 trial) 258 Cisplatin, capecitabine and cetuximab plus radiation vs cisplatin and capecitabine plus radiation 1.53 (0.035) 22.1 months vs 25.4 months
Okines et al 28 1,103 ECX and bevacizumab vs ECX NR NR
*

HR: Hazard ratio; OS: Overall survival; ECX: Epirubicin, Cisplatin and Capecitabine.